Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2026-03-25 Board/Management Inform…
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
General Updates
Board/Management Information Classification · 95% confidence The document is a formal announcement dated 25th March 2026 from Sanofi India Limited addressed to stock exchanges. It reports the outcome of a Board Meeting held on the same day. The key points include the approval to convene the 70th Annual General Meeting (AGM), details about the final dividend recommendation subject to AGM approval, and the appointment of a new Additional and Independent Director, Mr. Siraj Azmat Chaudhry, subject to shareholder approval at the AGM. The document includes detailed disclosures required under SEBI regulations about the director's appointment and profile. The document does not contain financial statements or detailed financial performance data but is primarily an announcement of board decisions and appointments. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results announcement. The primary content is about board decisions and management changes, specifically the appointment of a new director. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (9022 characters) supports it being a detailed announcement rather than a brief notice or a report publication announcement.
2026-03-25 English
Please refer the attachment
Board/Management Information Classification · 95% confidence The document is a formal announcement dated 25th March 2026 from Sanofi India Limited addressed to stock exchanges. It reports the outcome of a Board Meeting held on the same day. The key points include the approval to convene the 70th Annual General Meeting (AGM), declaration of a final dividend subject to AGM approval, and the appointment of a new Additional and Independent Director, Mr. Siraj Azmat Chaudhry, subject to shareholder approval at the AGM. The document includes detailed disclosures required under SEBI regulations about the director's appointment, his profile, and compliance confirmations. The document does not contain financial statements or detailed financial performance data but is primarily an announcement of board decisions and appointments. It is not a full annual report, audit report, or earnings release. It is not a proxy solicitation or voting results declaration. The primary content is about board decisions and management changes, specifically the appointment of a new director. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (9022 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2026-03-25 English
Please refer the attachment
Board/Management Information Classification · 95% confidence The document is a formal announcement dated 25th March 2026 from Sanofi India Limited addressed to stock exchanges. It reports the outcome of a Board Meeting held on the same day. The key points include the approval to convene the 70th Annual General Meeting (AGM), declaration of a final dividend subject to AGM approval, closure of the register of members, and appointment of a new Additional and Independent Director, Mr. Siraj Azmat Chaudhry, subject to shareholder approval at the AGM. The document includes detailed disclosures required under SEBI regulations about the director's appointment and profile. There are no financial statements or detailed financial performance data presented. The document is primarily an announcement of board decisions, including management changes and dividend proposals, rather than a full report or financial statement. Therefore, it fits best under the category of Board/Management Information (MANG), as it announces a change in the company's board of directors and related corporate actions.
2026-03-25 English
Please refer the attachment
Board/Management Information Classification · 95% confidence The document is a formal announcement dated 25th March 2026 from Sanofi India Limited addressed to stock exchanges. It reports the outcome of a Board Meeting held on the same day. The key points include the approval to convene the 70th Annual General Meeting (AGM), details about the final dividend recommendation subject to AGM approval, and the appointment of a new Additional and Independent Director, Mr. Siraj Azmat Chaudhry, subject to shareholder approval at the AGM. The document includes detailed disclosures required under SEBI regulations about the director's appointment and profile. There are no financial statements or detailed financial performance data presented. The document is primarily an announcement of board decisions, including management changes and dividend proposals, rather than a full report or financial statement. Therefore, it fits best under the category of Board/Management Information (MANG), as it announces changes in the company's board and related governance matters.
2026-03-25 English
Appointment
Board/Management Information Classification · 95% confidence The document is a formal announcement dated 25th March 2026 from Sanofi India Limited addressed to stock exchanges (BSE and NSE). It reports the outcome of a Board Meeting held on the same day. The key points include the approval to convene the 70th Annual General Meeting (AGM), declaration of a final dividend subject to AGM approval, closure of the register of members, and appointment of a new Additional and Independent Director, Mr. Siraj Azmat Chaudhry, subject to shareholder approval at the AGM. The document includes detailed disclosures required under SEBI regulations about the director's appointment, his profile, and compliance confirmations. The document does not contain financial statements or detailed financial performance data but is primarily an announcement of board decisions and appointments. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a voting result declaration but an announcement of the Board Meeting outcome including the intention to hold the AGM and seek shareholder approval for dividend and director appointment. Therefore, the document best fits the category of Board/Management Information (MANG), as it announces changes in the company's board and other board decisions.
2026-03-25 English
Please refer the attachment
Board/Management Information Classification · 95% confidence The document is a formal announcement dated 25th March 2026 from Sanofi India Limited addressed to stock exchanges. It reports the outcome of a Board Meeting held on the same day. The key points include the approval to convene the 70th Annual General Meeting (AGM), declaration of a final dividend subject to AGM approval, closure of the register of members, and appointment of a new Additional and Independent Director, Mr. Siraj Azmat Chaudhry, subject to shareholder approval at the AGM. The document includes detailed disclosures required under SEBI regulations about the director's appointment and profile. The document does not contain financial statements or detailed financial performance data but is an official announcement of board decisions, including management changes and dividend proposals. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results declaration. The primary content is the announcement of board meeting outcomes, including management appointment and dividend proposal, which fits best under Board/Management Information (MANG). The document length (9022 characters) and content confirm it is not a brief report publication announcement or a certification. Therefore, the classification is MANG with high confidence.
2026-03-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.